July 25, 2023
1 min watch
Save
VIDEO: Long-term follow up scrutinizes rituximab maintenance for mantle cell lymphoma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Jakub Svoboda, MD, discusses a study presented at ASCO Annual Meeting that evaluated rituximab maintenance for young patients with mantle cell lymphoma.
The study evaluated median OS, EFS and PFS over a median 7-year period in 299 patients. Researchers found that PFS remained, but OS did not.
"The whole field of mantle cell lymphoma is evolving, and we’ll see how the rituximab maintenance, whether it will continue to be part of our practice," Svoboda, associate professor of medicine at Hospital of the University of Pennsylvania, said.
Reference :
- Sarkozy C, et al. Abstract 7508. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Svoboda reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.